Recently, Shengshi Taike announced the completion of the first round of over 100 million yuan C-round financing. The investor in this round is Tongren Boda, and the funds raised will be used for the commercial production and sales of the company's upcoming Class 1 innovative drug product, sengliptin (formerly known as Shenggliptin), as well as the clinical development of the subsequent innovative product pipeline.

Shengshi Taike is a biotechnology company in the commercial stage, with a core team that has decades of experience in the entire lifecycle of international drugs. We are committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.

At present, the company's independently developed new generation of highly selective DPP-4 inhibitor, sengliptin, is about to be approved for market. Its clinical results show that compared with similar drugs already on the market, its "dosage" half work effect is expected to become the best hypoglycemic drug in its class; What is even more valuable is that its safety further solves the common adverse reactions in products already on the market.

The successful development of sengliptin has verified the innovation and feasibility of the company's research and development platform. Based on this platform, the company has also developed multiple anti-tumor drugs that have entered the clinical stage. Among them, the CXCR4 antagonist CGT-1881 is used for hematopoietic stem cell mobilization and is the only original small molecule oral CXCR4 antagonist in China; The FGFR/VEGFR dual target inhibitor CGT-6321 is expected to become a potential first in class drug for the treatment of solid tumors. Among these products, two drugs have obtained clinical trial approval from the US FDA, and this financing will also accelerate the company's pace of innovation going global.

In the current environment of biomedicine, Shengshi Taike has achieved over 100 million yuan in financing against the trend, demonstrating the high recognition of investors for the company's innovation and industrialization capabilities. You Ronghui, a partner of Boda, the investor in this round, said: "With the aging of China's population structure and the improvement of its economic level, we are very optimistic about the development prospects in the fields of metabolism and anti-tumor. Especially in the hypoglycemic drug market, as the region with the largest number of diabetes patients, there is a strong domestic demand for innovative drugs with better efficacy and better safety. At the critical moment when the company's core products are listed, we believe that this round of financing can help enterprises successfully open the road to commercialization, and drive the rapid advancement of other innovative products, to write a new chapter in the company's development."